Johnson & Johnson (JNJ) analyst actions
Rating and price-target actions on JNJ in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the JNJ overview →
3 measured JNJ analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis | Press release | +0.05% | +0.16% | |
| FDA Panel Reiterates the Cancer Risks of Talc | Press release | -0.15% | -0.04% | |
| New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer | Press release | +0.32% | -0.23% |
Keep exploring
More JNJ: earnings → · SEC filings → · JNJ overview →
Other Health Care names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Eli Lilly (LLY) | 2,000+ | +0.03% | 52% |
| UnitedHealth Group (UNH) | 2,000+ | -0.03% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.